A new publication involving triptorelin was listed on October 18, 2026. The study, titled "Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study," appeared in Urologic Oncology.
Triptorelin is classified as an LHRH agonist, a drug class referenced in the study title. The publication is described as a retrospective cohort study examining cardiovascular events in patients with metastatic hormone sensitive prostate cancer.
The event record identifies this as a new publication entry, with the journal name, title, and date provided. No findings, outcomes, or comparative results from the study have been disclosed in this record. No statements about safety conclusions, risk differences, or clinical recommendations are included here.
Triptorelin remains an approved compound. This brief reports only that the listed publication has been recorded in Urologic Oncology on the stated date. Readers interested in the study details can consult the original publication through the source link provided separately.
For more background on this compound, see the linked overview page.